|
Injection Mold Tooling
CareFusion Corp., a leading, global medical device company, announced an agreement to acquire Medegen, a leading innovator in clinically differentiated needleless access valves and administration sets that deliver intravenous (IV) medication to patients, for $225 million in cash.
"Medegen is an ideal strategic fit with
CareFusion due to the complementary nature of our infusion product
lines, R&D investments, and our focus on products that are backed by
clinical evidence and differentiation," said David Schlotterbeck,
chairman and CEO of CareFusion. "With a global opportunity of more than
$2 billion for disposable IV sets, Medegen will expand our clinically
differentiated product line and add a new dimension to our existing
infection prevention portfolio. We will continue to invest in these
products to help hospitals reduce catheter-related blood stream
infections and catheter occlusions."
CareFusion is an industry leader in IV infusion
devices with its Alaris® system and Guardrails® safety software. Medegen
markets clinically proven, needle-free IV disposable products under the
MaxPlus™ and MaxGuard™ brands with patented technology designed to help
health care providers reduce CRBSI and prevent catheter occlusions.
Together, the companies have complementary product lines, research and
development expertise and proprietary technologies to help hospitals
improve the safe delivery of IV medications to patients.
CareFusion became a public company on Sept. 1,
2009 from the spinoff of Cardinal Health's Clinical and Medical Products
business. Since its formation, CareFusion has indicated plans to acquire
companies or technologies complementary to its industry leading
infusion, respiratory, dispensing and surgical products businesses.
Medegen would be its first acquisition.
CareFusion employs more than 15,000 people across
its global operations. More information may be found at
www.carefusion.com.
|